Why Is Jubilant Pharmova Share Price Falling Key Reasons 2026

The Jubilant Pharmova share price falling trend has become a key investor concern in 2026. With Jubilant Pharmova share price falling approximately 20 percent from its 52 week high of Rs 1,200 to current levels near Rs 964, investors are asking whether this correction represents a buying opportunity or signals deeper structural challenges. Jubilant Pharmova (NSE: JUBLPHARMA), listed in the Pharmaceutical and Radio Pharmaceuticals space, has witnessed sustained selling pressure through FY26.

Click Here Get Free Investment Predictions

About Jubilant Pharmova

Pharmaceutical company with radio-pharma, allergy therapy, CDMO and generic businesses. Revenue Rs 4,500 crore. 52W high Rs 1,200, CMP Rs 964, down 20 percent. The stock is trading at approximately Rs 964, down approximately 20 percent from its 52 week high of Rs 1,200. The 52 week low stands at Rs 750. The Jubilant Pharmova share price falling trend reflects both sector headwinds and company-specific pressures.

Parameter	Value
NSE Ticker	JUBLPHARMA
Sector	Pharmaceutical and Radio Pharmaceuticals
CMP (2026)	Rs 964
52 Week High	Rs 1,200
52 Week Low	Rs 750
Decline from 52W High	Approximately 20 percent
Market Cap	Rs 6,000 crore (approx)
Trailing P/E	18x

Why Is Jubilant Pharmova Share Price Falling: Key Reasons

Use the Univest Screener to check live fundamentals of Jubilant Pharmova and compare with peers.

1. Q4 FY26 Results and Earnings Deceleration

A key driver behind the Jubilant Pharmova share price falling is the deceleration in earnings growth relative to the elevated expectations priced in at its 52 week high of Rs 1,200. Revenue and profitability have come under pressure from input cost inflation, competitive pricing constraints, and higher operating expenditure. The market is now recalibrating to a more moderate earnings trajectory, which has become a core driver of the Jubilant Pharmova share price falling below prior analyst targets.

2. FII Selling and Broad Market Correction

The US reciprocal tariff announcement imposing a 26 percent levy on Indian goods triggered a broad FII selloff from Indian equities. The Jubilant Pharmova share price falling by 20 percent from its peak reflects the combination of macro-level FII selling and company-specific headwinds. FII outflows from the Pharmaceutical and Radio Pharmaceuticals sector have been particularly pronounced, amplifying the correction in Jubilant Pharmova.

3. Sector-Specific Headwinds in Pharmaceutical and Radio Pharmaceuticals

The Pharmaceutical and Radio Pharmaceuticals sector faced its own challenges in FY26, with analyst earnings estimates revised downward as input cost inflation, competitive pricing pressures, and demand moderation weighed on sector outlook. This sector de-rating has driven the Jubilant Pharmova share price falling trend throughout 2026 as institutional investors reduced overall sector exposure.

4. Valuation De-Rating from Peak Multiples

At its 52 week high of Rs 1,200, Jubilant Pharmova was trading at valuation multiples above its historical average. As results came in below peak expectations and sector sentiment turned cautious, the market applied lower multiples to Jubilant Pharmova earnings. This valuation de-rating from Rs 1,200 to Rs 964 is one of the core mechanisms behind the 20 percent correction in the Jubilant Pharmova share price falling phase.

5. Small and Mid Cap Liquidity Squeeze

With a market capitalisation of approximately Rs 6,000 crore, Jubilant Pharmova is exposed to the liquidity dynamics of the small and mid cap segment, which experienced a sharp liquidity squeeze in FY25-26. When domestic mutual funds face redemption pressure and retail investors turn risk-averse, smaller companies bear disproportionate selling pressure, amplifying the Jubilant Pharmova share price falling trend.

6. Global Macroeconomic Uncertainty

India’s equity market in FY26 faced macro headwinds including global tariff wars, crude oil price volatility, and currency pressure. The Jubilant Pharmova share price falling trend has been reinforced by this macro overhang that keeps institutional buyers cautious even when individual company fundamentals do not fully justify the magnitude of the decline.

Financial Performance Analysis of Jubilant Pharmova

The key financial metrics driving the Jubilant Pharmova share price falling narrative are visible in both recent quarterly trends and valuation de-rating. The stock has fallen 20 percent from its 52 week high of Rs 1,200 to Rs 964. The market cap has contracted to approximately Rs 6,000 crore. Investors tracking the Jubilant Pharmova share price falling should monitor Q4 FY26 results and management commentary on margin and revenue recovery.

Key Metric	Current Level	52 Week Peak	Trend
Share Price	Rs 964	Rs 1,200	Down 20 percent
Market Cap (Rs Cr)	Rs 6,000 crore	Higher at 52W peak	Compressed with price
Trailing P/E	18x	Higher at 52W high	Multiple compressed
52 Week Range	Rs 750 to Rs 1,200

Technical Signals What the Charts Are Saying

On the technical charts, the Jubilant Pharmova share price falling pattern is confirmed by the stock trading below its 50 day, 100 day, and 200 day simple moving averages, which are sloping downward. Since its 52 week high of Rs 1,200, Jubilant Pharmova has formed a pattern of lower highs and lower lows. Key support is at the 52 week low of Rs 750. Overhead resistance is at the Rs 1,200 zone. Download the Univest iOS App or Univest Android App to track Jubilant Pharmova live price and get daily stock recommendations.

Can Jubilant Pharmova Share Price Recover

Despite the headwinds driving the Jubilant Pharmova share price falling, recovery catalysts exist. A quarterly earnings result beating reduced analyst expectations could trigger a short-covering rally from oversold levels. Any positive inflection in the Pharmaceutical and Radio Pharmaceuticals sector, reversal of FII selling as global macro conditions improve, or a broader small and mid cap recovery could arrest the Jubilant Pharmova share price falling trend. At Rs 964, a significant portion of the bad news may already be priced in, creating a potentially attractive entry point for patient investors with a 2 to 3 year horizon.

Conclusion

The Jubilant Pharmova share price falling by approximately 20 percent from its 52 week high of Rs 1,200 to the current Rs 964 reflects broad market headwinds, FII selling, earnings impact, and valuation de-rating. Investors monitoring the Jubilant Pharmova share price falling should closely watch upcoming earnings guidance, FII ownership shifts, and macro signals for any sustainable reversal. For real-time tracking, visit Univest.

Disclaimer Note: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Data sourced from publicly available open sources and may not be completely accurate. SEBI Registration No. INH000013776.

Frequently Asked Questions

Why is Jubilant Pharmova share price falling in 2026?

Ans. The Jubilant Pharmova share price falling in 2026 is driven by FII selling following the US tariff announcement in 2026, sector headwinds in the Pharmaceutical and Radio Pharmaceuticals space, earnings deceleration, and valuation de-rating from peak multiples. The decline totals approximately 20 percent from the 52 week high of Rs 1,200 to the current Rs 964.

What is the 52 week high and low of Jubilant Pharmova?

Ans. The 52 week high of Jubilant Pharmova is Rs 1,200 and the 52 week low is Rs 750. The current price of approximately Rs 964 represents a decline of about 20 percent from the 52 week high.

Should I buy Jubilant Pharmova shares at current levels?

Ans. Whether to buy Jubilant Pharmova at Rs 964 during the Jubilant Pharmova share price falling phase depends on your investment horizon and risk appetite. The stock has fallen 20 percent from its peak. Always consult a SEBI registered financial advisor before making any investment decision.

What are the recovery triggers for Jubilant Pharmova?

Ans. Key recovery catalysts for Jubilant Pharmova include a quarterly earnings result beating reduced analyst expectations, reversal of FII selling as global macro conditions improve, positive sector re-rating in the Pharmaceutical and Radio Pharmaceuticals space, and a broader Indian market recovery.

What are the key downside risks to Jubilant Pharmova stock?

Ans. Key downside risks include continued earnings estimate downgrades, further FII selling, unexpected regulatory or competitive developments in the Pharmaceutical and Radio Pharmaceuticals sector, and a deeper correction in the broader Indian equity segment testing the 52 week low of Rs 750.

What is the market cap of Jubilant Pharmova?

Ans. The current market capitalisation of Jubilant Pharmova is approximately Rs 6,000 crore based on the current price of Rs 964. The market cap has compressed from its peak levels as the Jubilant Pharmova share price falling trend has persisted through 2026.